Thermotraumaport Limited Secures £59.9k Series A to Advance Trauma Patient Transfer Technology

Ashford-based medical device manufacturer Thermotraumaport Limited has completed a Series A funding round, raising an estimated £59.9k. The investment brings the company to an estimated post-money valuation of £2.1m. The shares were allotted on March 23, 2026, and the round was officially filed today, March 26, 2026.

Founded in August 2014, Thermotraumaport Limited specialises in the development and production of the ThermoTraumaPort. The hardware is a dedicated medical transfer device engineered to provide active warming while significantly reducing the need to repeatedly handle trauma patients during transport and medical imaging.

The company targets a critical operational challenge in emergency medicine. When treating severe trauma, maintaining a patient's core body temperature is vital to prevent trauma-induced hypothermia, a condition that can severely complicate recovery and increase mortality rates. Furthermore, minimising physical transfer and handling reduces the risk of exacerbating spinal or internal injuries. By addressing both active warming and stable transport, Thermotraumaport serves military organisations, emergency medical services, and hospital trauma departments, aiming to improve patient outcomes across both pre-hospital and in-hospital environments.

Financial metrics such as current revenue, profit and loss figures, and exact employee headcounts were not disclosed in the latest filings. The identities of the investors participating in this Series A round have also not been made public, and the company has not disclosed details of prior funding rounds.

The £59.9k capital injection arrives during a period of recalibration and growth for the broader UK health technology and medical device sectors. According to the Startup Coalition's 2025 HealthTech Index, UK health tech startups reached a combined valuation of £32 billion by the end of 2024, supported by a workforce of nearly 30,000 people. Within this ecosystem, health-related hardware remains a substantial segment, with 150 active startups and scaleups raising a combined £3.1 billion historically. However, hardware development requires significant capital to navigate complex regulatory frameworks and manufacturing pathways.

Industry forecasts project the UK MedTech market alone will reach £15.7 billion in value by the end of 2025, growing steadily toward £20.5 billion by 2030. Despite this macro-level growth, market analysts note that securing Series A and Series B funding remains one of the most challenging hurdles for UK health tech enterprises. Following a broader venture capital reset, investors are increasingly shifting away from speculative models, instead prioritising clinical validation, operational efficiency, and clear procurement pathways. For hardware developers like Thermotraumaport, securing Series A backing is a necessary step to fund the rigorous testing, compliance, and commercialisation efforts required to deploy medical devices into highly regulated environments such as the NHS and military supply chains.